[HTML][HTML] Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study
CW Xu, WX Wang, D Wang, QM Wang… - … lung cancer research, 2020 - ncbi.nlm.nih.gov
Background Chemotherapy is the major choice for advanced non-small-cell lung cancer
(NSCLC) patients with epidermal growth factor receptor exon 20 insertion (EGFR ex20ins) …
(NSCLC) patients with epidermal growth factor receptor exon 20 insertion (EGFR ex20ins) …
Design, synthesis and antitumor activity of icotinib derivatives
L Mao, G Sun, J Zhao, G Xu, M Yuan, YM Li - Bioorganic Chemistry, 2020 - Elsevier
EGFR-TK pathway is of high importance for the treatment of non-small-cell lung cancers
(NSCLC), and it will be challenging to develop anti-tumor drugs that could inhibit both EGFR …
(NSCLC), and it will be challenging to develop anti-tumor drugs that could inhibit both EGFR …
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma
H Lu, B Zhang, Y Xie, W Zhao, W Han, L Zhou… - Investigational New …, 2023 - Springer
Glioblastoma (GBM) is a highly lethal neurological tumor that presents significant challenge
for clinicians due to its heterogeneity and high mortality rate. Despite extensive research …
for clinicians due to its heterogeneity and high mortality rate. Despite extensive research …
[HTML][HTML] Comprehensive comparison between adjuvant targeted therapy and chemotherapy for EGFR-mutant NSCLC patients: a cost-effectiveness analysis
W Li, H Guo, L Li, J Cui - Frontiers in Oncology, 2021 - frontiersin.org
Background: Chemotherapy has been the current standard adjuvant treatment for early-
stage non-small-cell lung cancer (NSCLC) patients, while recent studies showed benefits of …
stage non-small-cell lung cancer (NSCLC) patients, while recent studies showed benefits of …